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Abstract 
Background:   Worldwide, after malaria and sleeping sickness, leishmaniases are the third most important vector 
borne diseases. Visceral leishmaniasis (kala- azar) is a disseminated protozoan infection caused by L. donovani, L. 
infantum, or L. arachibaldi, and transmitted by the female phlebotomine sand fly bite.  Coinciding with HIV infection, 
the number of visceral leishmaniasis cases in Ethiopia has increased in the last decade. 
Objective:  To assess the clinical and laboratory manifestations and factors associated with mortality and morbidity of 
visceral leishmaniasis with or without HIV co-infection. 
Methods:  A hospital-based case series study of visceral leishmaniasis assessing clinical manifestations, laboratory 
data, treatment outcomes and HIV sero-status was conducted in Gondar University Teaching Hospital over a period of 
five years and seven months (from January 1999 to July 2004). 
Results:  A total of 221 kala-azar patients participated in the study.  Out of 212 visceral leishmaniasis cases tested for 
HIV, 87(41.0%) were HIV co-infected.  Age > 20 years was independently associated with HIV co-infection.  Out of 
213 kala-azar patients treated with sodium stibogluconate (SSG), 52 died, resulting in a case fatality rate of 24.4%.  
The case fatality rates among HIV positive and HIV negative kala-azar cases were 39.3% and 13.0%, respectively.  
Using logistic regression, HIV infection, body mass index (BMI) of 15 and below, bleeding tendency, and age > 20 
years were identified as independent variables predicting death. 
Conclusion and recommendation:  HIV co-infection and the case fatality rates are very high among patients with 
Visceral leishmaniasis. We recommend further study and improved care for HIV co-infected visceral leishmaniasis 
cases.  [Ethiop.J.Health Dev. 2007;21(1):53-60] 
 
Introduction 
Leishmaniases are parasitic diseases caused by obligate 
intracellular protozoa of the genus leishmania.  After 
malaria and sleeping sickness, leishmaniases are the third 
most important vector-born diseases accounting for an 
estimated 1.98 million disability adjusted life years and 
57,000 deaths per annum (1). 
 
Leishmaniasis is endemic in 88 countries of five 
continents: Africa, Asia, Europe, North America and 
South America, with a total of 350 million people at risk.  
Worldwide, 12 million people are affected, with or 
without apparent symptoms.  Of the 1.5 to 2 million new 
cases of leishmaniasis estimated to occur annually, only 
600,000 are officially declared (2). 
 
In the past 20 years, the number of human leishmaniasis 
cases has dramatically increased with a trend that shows 
no sign of abating (3).  This increase might be due to two 
main factors.  The first is the adaptation of the leishmania 
transmission cycle to peridomestic environments as a 
response to deforestation and urbanization (4).  The other 
factor is that leishmaniasis is a common opportunistic 
infection in HIV-infected persons (5). 
 
Visceral leishmaniasis (VL) (kala-azar) is a disseminated 
protozoan infection, transmitted by sand fly bites, in 
which macrophages of the liver, spleen and bone marrow 
are preferentially parasitized with intracellular replication 
(6).  Leishmania donovani is the primary cause of 
visceral leishmaniasis in the Indian subcontinent and east 
Africa (7). 
 
Visceral leishmaniasis is characterized by irregular bouts 
of fever, substantial weight loss, swelling of the spleen 
and liver, and anemia.  If left untreated it is a 100% fatal 
illness (2,8).  VL is endemic in 62 countries with a total 
of 200 million people at risk (9).  World wide 500,000 
new cases of visceral leishmaniasis occur annually, of 
which 90% are found in five countries, namely 
Bangladesh, Brazil, India, Nepal and Sudan (2).  There 
were 41,000 recorded deaths in the year 2000 alone (9). 
 
In Ethiopia, a small outbreak of visceral leishmaniasis 
was reported among migrant agriculture laborers near the 
Sudanese border of Northwest Ethiopia in 1978 (10).  VL 
has since been reported from seven of the 16 
administrative regions by 1990 (11). Between 1982 and 
1990, 149 cases were reported from the Aba Roba focus 
in the Konso area, South Ethiopia and up to August 1990, 
a total of 285 cases were recorded by the Institute of 
Pathobiology in Addis Ababa (11).  Coinciding with the 
HIV epidemic, the burden of visceral leishmaniasis has 
dramatically increased in Ethiopia over the last 10 years 
(12-14).  In 1996, 7 cases of VL and HIV co-infection 
were reported (15); in 2002, among 103 VL cases about 
51% were HIV positive (12).  Between 1998 and 2000, 
839 cases were diagnosed to have VL and out of 213 
tested for HIV, 49(23%) were co-infected in Humera, the 
Tigray region bordering Sudan and Gondar (16). 
HIV/AIDS and VL are locked in a vicious cycle of 
natural reinforcement, where VL quickly accelerates the 
onset of AIDS and HIV spurs the spread of VL.  AIDS 
increases the risk of VL by 100-1000 times in endemic 
areas (2, 17, 18, and 19). 
 
The objective of this study is to assess the clinical and 
laboratory manifestations and factors associated with 
mortality and morbidity of visceral leishmaniasis, with or 
without HIV co-infection.  The treatment outcomes will 
be described.  To our knowledge, this is the first such 
large case series hospital-based study in the country, in 
general, and in Gondar in particular.  Moreover, the 
similarities and differences in the clinical and laboratory 
manifestations of visceral leishmaniasis with or without 
HIV co-infections will be described. 
 
Methods 
Study subjects and area:  All 221 patients with visceral 
leishmaniasis diagnosed and or treated in medical wards 
of Gondar University tertiary level teaching and referral 
hospital, from January 1999 to July 2004 (5 years and 7 
months duration) were included.  Gondar University 
Hospital is located in Gondar town 750 km Northwest of 
Addis Ababa.  The hospital has 400 inpatient beds and 
provides health referral services for over 4 million 
inhabitants in the northwest region of Ethiopia. 
 
Study design and data collection:  This is a hospital-
based case series study in the routine care of patients.  A 
pre-tested and standardized questionnaire consisting of 
demographic data, clinical symptoms and signs, 
laboratory data, treatment response and outcomes, was 
used for data collection.  In all cases, pre- and post-test 
counseling was given irrespective of HIV status.  On-
going counseling was arranged for HIV positive patients.  
A standard dose of sodium stibogluconate (SSG) was 
administered for 30 days as treatment for VL.  Whenever 
SSG was not available, patients were referred to other 
treatment centers such as MSF Holland in Humera or 
Dansha (eight patients).  Transport fees and supportive 
care such as blood transfusion and treatment of 
intercurrent infections were given. 
 
Diagnosis of VL and HIV:  VL diagnosis was made 
based on clinical parameters and confirmed by spleen or 
bone marrow aspirations as appropriate.  Pathologists 
and/or senior clinicians read the aspirates at least twice.  
Wright or Giemsa staining was used as available in the 
hospital.  Direct agglutination test (DAT) with treatment 
response was used in five cases only, using the 
methodology and Leishmania donovani test antigen  
prepared in the Institute of Pathobiology as described by 
Harith et al (1988).  A titer of 1:3200 was used as a 
threshold cut off value.  In all the five cases, the response 
to treatment with sodium stiboglutinate was dramatic, as 
the spleen and other symptoms and signs disappeared.  
All five cases had no other diagnosis or treatment other 
than the ones for VL. For HIV testing, Determine Abbot 
Japan and Cappilus - rapid tests and ELISA were used in 
the hospital.  The policy of the department of internal 
medicine required testing for HIV in all cases of visceral 
leishmaniasis, in order to anticipate drug toxicity and 
individualize the care accordingly. 
 
The study included follow up at 3 and 6 months, however 
participation in the follow up sessions was very low.  
This is because many of the cases were mobile 
agriculture laborers or farmers residing far from the 
hospital and with no permanent address.  The follow up 
sessions also coincided with the rainy and harvesting 
seasons. Moreover, there was no tracing mechanism in 
place to actively search for participants for follow up.   
 
Ethical clearance:  Informed consent was obtained from 
all patients and institutional ethical clearance was 
obtained from the research and publication office of 
Gondar University. 
 
Operational definitions:  Clinical response (initial cure) 
criteria for successful treatment and discharge from the 
hospital included disappearance of fever, marked 
regression of spleen size, significant weight gain, 
hematological response, and cessation of hemorrhagic 
diathesis. 
 
Spleen size of 15 cm and above is defined as a huge 
splenomegaly, and is associated with infarction, anemia 
and dragging abdominal pain. 
 
Hematocrit level of 15% and below is taken as severe 
anemia with congestive heart failure or pending heart 
failure that requires transfusion before SSG therapy; 
hematocrit level of 16% to 25% is moderate anemia.  
 
Lymphocytosis is defined as the differential white cell 
count of lymphocytes more than 50%; granulocytosis is 
defined as a count of granulocytes above 50%. 
 
Data analysis:  Data entry and analysis was performed 
using Epi Info 2002 and SPPS version 10.0 statistical 
packages.  Logistic regressions were run to determine 
factors predicting HIV or death.  Odds ratios and chi 
square, with p-value<0.05 and a 95% confidence interval 
were used for statistical analysis and significance testing. 
 
Results 
From January 1999 to July 2004, there were 8,049 
admissions and 1,334 deaths within the medical wards of 
Gondar University Hospital.  Of these, 221 were visceral 
leishmaniasis cases, accounting for about 2.8% of the 
admissions and 52(3.9%) deaths in the medical wards. 
The male to female ratio was 19:1 and the mean age was 
25.7±7.8 years (range 14-55 years).  Two hundred and 
six (93.2%) of the cases were under 40 years of age and 
119(53.8%) were in the 20-29 age group, followed by 
44(19.9%) in the 10-19 age group (Table 1). 
 
Of 212(95.9%) VL patients who agreed to HIV testing, 
87(41.0%) were HIV positive.  Of those with both 
infections, 85(42.3%) were males.  HIV co-infection was 
found in 65.5% (83/58) of those older than 29 years 
(Table 1). 
 
With respect to occupational categories, 111(50.2%) 
were farmers, 36(16.3%) were daily laborers, 19(8.6%) 
soldiers and 17(7.7%) students.  All of the five civil 
servants among the study population were HIV positive, 
as were 90.9% (10/11) of merchants, 63.6%(7/11) of 
drivers, 63.2%(12/19) of soldiers, 52.8%(19/36) of daily 
laborers and 29.8% (31.104) of farmers.  One of the nine 
housewives and two of the 17 students were HIV 
positive.  Seven farmers, one student, and one merchant 
either did not agree to the HIV test or died before 
screening (Table 1). 
 
Of the ninety-eight patients from Humera, Abderafi and 
Dansha area, 43.6% were HIV co-infected; 34.8% of the 
73 patients from the Metema-Chilga were HIV positive. 
Of the fifty patients from other places in the Amhara 
region, mainly from North Gondar, 44.9% were also HIV 
positive (table 1).  Many of these cases had a history of 
travel to Humera of Metema either recently or some 
years ago.  However, there were a few cases from 
Belessa and around the Gondar area that had no travel 
history to Humera. A 14 year old male from Gondar 
town, sero-negative for HIV, denied any travel out of 
town in his lifetime. 
 
Of all the VL cases, 87(39.4%) were seen in 2003, 55 
(24.9%) in 2002, and a total of 30 (13.6%) in the period 
between 1999 and 2001.  In the seven months of 2004 
during which this study was conducted, forty nine 
(22.1%) cases were seen. These numbers indicate an 
increasing trend of VL cases over the years (Figure 1). 
 
Out of 222 total cases, 178(80.5%) were diagnosed by 
splenic aspiration, 38(17.2%) by bone marrow spiration 
and five (2.3%) by serum direct agglutination test. 
 
All visceral leishmaniasis patients complained of a 
history of generalized body weakness.  Similarly, all 
cases had a history of fever with a mean duration and 
temperature of 12.6±8.9 weeks and 380C±10C, 
respectively.  Splenomegaly was found in all patients 
with a mean size of 10.4±4.5 cm, below the constal 
margin along the left midclavicular line.  Hepatomegaly 
was seen in 104(47.1%) patients, with a mean total liver 
span at right midclavicular line of 14.4±1.5 cm.  A 
history of weight loss over a mean duration of 13.4±10.1 
weeks and a mean body mass index of 15.5Kg/sq.m was 
observed in 218(98.6%) patients, despite the good 
appetite reported by 60(27.3%) patients.  About 
195(88.2%) had signs of anemia (pallor), with a mean 
hematocrit of 22.1±6.6%.  History of bleeding tendency 
from any site was found in 119(53.8%) cases; the most 
common was epistaxis (76.4% of cases), followed by 
 
Table 1:  Sociodemographic characteristics of visceral leishmaniasis patients by HIV serostatus, Gondar University 
Hospital, 1999-2004. 






Total screened for 
HIV No (%) 
Sex     
     Male 210(95.0) 85(42.3) 116(57.7) 201(94.8) 
     Female  11(5.0)  2(18.2)   9(81.8)  11(5.2) 
Age interval     
     10-19  44(19.9) 5(12.8)  34(87.2)  39(18.4) 
     20-29 119(53.8) 44(38.3)  71(61.7) 115(54.4) 
     30-39  43(19.5) 26(60.5)  17(39.5)  43(20.3) 
     40-49  11(5.0)  8(72.7)   3(27.3)  11(5.2) 
     50-59   4(1.8)  4(100.0)   0   4(1.9) 
Occupation     
     Farmer 111(50.2) 31(29.8)  73(70.2) 104(49.1) 
     Daily laborer  36(16.3) 19(52.8)  17(47.2)  36(17.0) 
     Soldier  19(8.6) 12(63.2)   7(36.8)  19(9.0) 
     Student  17(7.7)  2(12.5)  14(87.5)  16(7.5) 
     Merchant  12(5.4)  10(90.9)   1(9.1)  11(5.2) 
     Driver  11(5.0)  7(63.6)   4(36.4)  11(5.2) 
     Housewife   9(4.1)  1(11.1)   8(88.9)   9(4.2) 
     Civil servant   5(2.3)  5(100.0)   0   5(2.4) 
     carpenter   1(0.5)  0   1   1(0.5) 
Residency     
     Humera area  98(44.4) 41(43.6)  53(56.4)  94(44.3) 
     Metema area  73(33.0) 24(34.8)  45(65.2) 69(32.5) 
     Other areas 50(22.6) 22(44.9)  27(55.1) 49(23.1) 




















































Figure 1:  Visceral leishmaniasis, Gondar University Hospital, 1999-2004. 
 
gum and gastrointestinal tract bleeding in different 
combinations.  The least common clinical findings were 
coughing (32.6%), gray to dark skin color change 
(24.4%), diarrhea (21.7%), lymphadenopathy (19.9%) 
and jaundice (6.3%) (Tables 2 & 3). 
 
The mean age of HIV co-infected patients was 
significantly higher than those without co-infection 
(29.3±8.8 vs 23.6±6.1 years T=5.5, P<0.01).  The 
average spleen size in HIV positive cases was smaller 
(9.0±4.2 cm vs 11.0±4.7 cm, T+2.3, P<0.05).   
The mean hematocrit was significantly higher in those 
with HIV co-infection (23.5±7.1% vs 21.2±6.0%, T=2.5, 
P<0.05).  The mean differential count of neutrophils was 
higher (59.1±14.6% vs 50.4±16.8, T=e.8, P<0.01), 
whereas the lymphocyte count was lower (40.8±14.7% vs 
48.5±16.9, T=3.4, P<0.01) in VL cases with HIV co-
infection compared to the lymphocyte count in HIV 
negative VL cases.  The mean platelet count was 
67.283±45,073/mm3.  Likewise, the mean white cell 
count was 2,465±1,431/mm3 with a mean differential 
count of neutrophils and lymphocytes of 53.9±16.6% and 
45.3±16.5%, respectively (Table 3). 
 
Table 2:  Clinical parameters in visceral leishmaniasis patients, Gondar University Hospital, Northwest Ethiopia, 
1999-2004 
Clinical parameters Number (%) HIV positive (%) HIV negative (%) P-value 
Symptoms     
     Body weakness 221(100) 87(100.0) 125(100.0)  
     History of fever 221(100.0) 87(100.0) 125(100.0)  
     Weight loss 218(98.6) 87(100.0) 122(93.1)  
     Bleeding history 119(53.8) 47(54.0)  66(52.8)  
     Loss of appetite  60(27.3) 21(24.1)  34(27.2)  
     Cough  82(37.1) 34(39.1)  48(38.4)  
     Diarrhoea  48(21.7) 20(23.0)  28(22.4)  
Signs     
     Splenomegaly 221(100.0) 87(100.0) 125(100.0)  
     Pallor 195(88.2) 72(82.8) 114(91.2)  
     Hepatomegaly 104(47.1) 38(43.7)  62(49.6)  
     Skin change-gray/dark  54(24.4) 28(32.2)  25(20.0) 0.04 
     Lymphadenopathy  44(19.9) 22(25.3)  22(17.6  
     Jaundice  14(6.3)  6(6.9)   8(6.4)  
Table 3:  Mean clinical & laboratory values in visceral leishmaniasis patients with or without HIV co-infection, 
Gondar University hospital, 1999-2004 








mean S.D mean S.D T-test P-value 
Age (years) 25.7 7.8 29.3 8.8 23.6 6.1 5.5 0.0000 
Temperature (0C) 38.1 1.0 38.0 0.9 38.1 1.0 0.8 0.4 
BMI (Kg.m2) 15.5 2.4 15.5 2.6 15.4 2.3 0.3 0.8 
Wight loss (kg)  7.9 3.6  8.3 3.6 7.8 3.5 0.8 0.4 
Spleen size (cm) 10.4 4.5  9.0 4.2 11.0 4.7 2.3 0.02 
Total liver span (cm) 14.4 1.5 14.2 1.4 14.5 1.6 0.9 0.4 
Fever duration (weeks) 12.6 8.9 13.1 9.7 12.4 8.4 0.5 0.6 
Weight loss duration (weeks) 13.4 10.1 14.8 11.9 12.3 8.5 1.7 0.08 
White cell count (No/mm3) 2465 1431 2,434 1139 2,543 1,619 0.5 0.6 
Granulocytes (%) 53.9 16.6 59.1 14.6 50.4 16.8 3.8 0.0002 
Lymphocytes (%) 45.3 16.5 40.8 14.7 48.5 16.9 3.4 0.0009 
Hematocrit (%) 22.1 6.6 23.5 7.1 21.3 5.9 2.5 0.01 
Platelet count (No/mm3) 67,283 45,074 78,389 41.794 62,724 48,875 1.4 0.2 
 
Bivariate analysis identified 6 variables that were 
significantly associated with HIV co-infection: age > 20 
years, spleen size of 15cm and below, hematocrit of 25% 
and above, granulocytes of 50% and below, lymphocytes 
at 50% and below, and dark to gray skin color change.  
Using a logistic regression model, only age > 20 years 
was found to be an independent predictor of HIV co-
infection (OR=3.2, 95% CI=1.6-6.3, P<0.001) (Table 4). 
 
Sodium stibogluconate was given to 213(96.5%) visceral 
leishmaniasis patients.  Eight patients (3.6%) were 
referred to other centers after diagnosis and stabilization, 
as the drug was not available in the hospital.  From the 
treated cases, 157(73.7%) were declared clinically cured, 
52(24.4%) died in the hospital and four reported back 
with relapse.  All the relapse cases were HIV positive.  
The case fatality rate among HIV co-infected patients 
was 39.3%, whereas it was 13.3% in HIV negatives 
patients (OR=2.1, CI=2.108.3).  The mean hematocrit 
was significantly lower in those who died (20.4±6.2% vs 
22.6±6.5, T=2.1 P<0.05).  The mean age was 
significantly higher (27.8±8.5 vs 25.0±7.5 year, T=2.2, 
P<0.05), while the mean body mass index was 
significantly lower (14.4±2.5 vs 15.8±2.3, T=3.8, 
P<0.01) in those who died compared to those that were 
cured.  Bleeding manifestation was significantly more 
common in those who died than in those who were cured 
(OR=2.6, 95% confidence interval=1.3-5.0, P<0.01).  
The same was true for manifestation of a dark/gray skin 
color change (Or=2.0, CI=1.0-3.9, P<0.05). 
 














Age group (year)       
     ≤20  67  52(77.6) 15(22.4) 1 1  
     >20 145  73(50.3) 72(49.7) 3.4(1.8-6.6) 3.2(1.6-6.30 0.000 
Spleen size (cm)       
     >15  28  23(82.1)  5(17.1) 1 1  
     ≤15 178  97(54.5) 81(45.5) 3.8(1.4-10.6 1.3(0.4-4.3) 0.7 
Hematocrit (%)       
     ≤25 154 100(64.9) 54(35.1) 1 1  
     >25  58  25(43.1) 33(56.9) 2.4(1.3-4.5) 1.5(0.8-2.8) 0.2 
Granulocytes (%)       
     <50  80  60(75.0) 20(25.0) 1 1  
     ≥50 126  61(48.4) 65(51.6) 3.2(1.7-5.9) 892.8(0.000-
1.7 E+16 
0.7 
Lymphocyte (%)       
     >50  76  58(76.3) 18(23.7) 1 1  
     ≤50 131  64(48.9) 67(51.1) 3.4(1.8-6.3) 1.8(0.2-3.5) 0.8 
Dark/gray skin color change       
     No 159 100(62.9) 59(37.1) 1   
     Yes  53  25(47.2) 28(52.8) 1.9(1.0-3.6) 0.5(0.2-1.0) 0.05 
 
 
Bivariate analysis also indicated that the six variables 
were associated with death during treatment.  A logistic 
regression model identified four of these variables as 
independent predictors of mortality.  These were HIV co-
infection (OR=4.2, 95% CI=2.8-8.9, P<0.001), body  
mass index of 15 and below (OR=3.3, 95% CI=1.5-7.5, 
P<0.005), bleeding tendency (OR=3.0, 95% CI=1.4-6.4, 
P<0.01) and age > 20 years (OR=2.3, 95% CI=1.0-5.3, 















HIV       
     Negative 120 104(86.7)  16(13.3) 1 1 0.000 
     Positive  84  51(60.7)  33(39.3) 4.2(2.1-8.3) 42(2.0-8.9)  
hematocrit (%)       
     >15 179 141(78.8)  38(21.2) 1 1  
     ≤15  34  20(58.8)  14(41.2) 2.6(1.2-5.6) 0.8(0.4-1.8) 0.7 
Age group (year)       
     ≤20  71  62(87.3)   9(12.7) 1 1  
     >20 142  99(69.7)  43(30.3) 3.0(1.4-6.6) 2.3(1.0-5.3) 0.049 
BMI (Kg/m2)       
     >15 122 103(84.4)  19(15.6) 1 1  
     ≤15  91  58(63.7)  33(36.3) 3.1(1.6-5.9) 3.3(1.5-7.5) 0.004 
Bleeding       
     No  97  83(84.5)  15(15.5) 1 1  
     Yes 116  79(68.1)  37(31.9) 2.6(1.3-5.0) 3.0(1.4-6.4) 0.005 
Dark/gray skin color change       
     No 161  18(34.6)  34(65.4) 1 1  
     Yes  52  34(21.1) 127(78.9) 2.0(1.0-3.9) 1.7(0.8-3.7) 0.2 
 
Discussion 
The number and rate of admission of visceral 
leishmaniasis patients to Gondar University Hospital has 
shown an increasing pattern over time (Figure 1).  
Visceral leishmaniasis is a significant cause of mortality 
accounting for 3.6% of hospital deaths.  There have been 
several epidemics of visceral leishmaniasis over the past 
few years in the neighboring country of Sudan which 
borders the two Ethiopian towns of Metema and Humera 
(20-23).  Any ties between the epidemics in the two 
countries remain to be proven.  Most of the patients in 
this study either came from, or had traveled to Metema 
and Humera as daily laborers, drivers, farmers, mobile 
merchants or soldiers.  Rural-urban migration, agro-
industrial and man-made projects like dams, irrigation 
systems and wells, as well as deforestation contribute to 
the spread of visceral leishmaniasis (2). 
 
The high rate of HIV co-infection, which was 41% in our 
patients, is a major reason for such an increased 
morbidity and mortality from VL.  The co-infection of 
leishmania and HIV is emerging as an extremely serious 
new disease and is increasingly frequent (24).  The 
overlapping geographic distribution of visceral 
leishmaniasis and AIDS is increasing due to the spread of 
the main factors of AIDS transmission to suburban and 
rural areas of the world, and the simultaneous spread of 
visceral leishmaniasis from rural to suburban areas, 
complicated by mass migration, displacement, civil 
unrest, war and malnutrition (2, 8, and 25).  Moreover, 
the immunological dysfunction caused by both 
leishmania and HIV augment the expression of one 
another.  Dual infection plays an important role in the 
pathogenesis and disease progression of both.  Both 
lieshmania and HIV exploit the immune regulatory 
networks of the host's immune system for their own 
progression.  Co-infection with leishmania in HIV 
infected subjects can affect the course of either one, or 
both diseases and it clearly contributes to a vicious cycle 
of uncontrolled immunosupression and disease 
progression (17, 18, and 26).  Immunological data 
indicate strong immunosupression of co-infected patients 
(27). 
 
The association with deforestation, agricultureal 
occupations, cattle grazing and seasonal migration of 
farmers and daily laborers, could explain the 
preponderance of VL in males.  Moreover, as women's 
access to the health services is limited, many cases of 
visceral leishmaniasis in women are likely to go 
undetected (7).  Close to 98% of HIV co-infections were 
in males, similar to the 1997 WHO report in which 90% 
of 692 co-infected cases were males (24). 
 
The productive age group (20-39 years) was most 
affected in this study.  Visceral leishmaniasis adversely 
affects productivity and welfare (7).  Similar to other 
studies, classic clinical manifestations of kala-azar  such 
as fever, weight loss and cachexia, splenomegaly, and 
pancytopenia were evident in our patients (8, 19, and 28).  
Hepatomegaly was found in 47.1% of cases and history 
of bleeding in 53.8% of cases.  Epistaxis accounted for 
76.4 of the bleeding.  Lymphadenopathy was found in 
22% of the VL patients in this study, which is much 
lower than the 1991 & 2002 studies from the Sudan, 
where it was in 84% and 86% of the patients respectively 
(22, 23). 
 
Patients aged > 20 years were more than 3 times as likely 
to have HIV infection as those 20 years and below.  The 
clinical features of VL/HIV co-infected patients closely 
resemble those of VL in immuno-competent hosts (29).  
However, our HIV co-infected patients were found to 
have smaller spleen sizes, higher neutrophils, lower 
lymphocyte differential counts, a lesser degree of anemia, 
and dark/gray skin color change when compared to HIV 
negative patients. 
 
In this study the over all case fatality rate was 24.4%, 
which is much higher than the report of 6.4% from Sudan 
in 1991 (22).  In 1978, the case fatality was 55.6% 
among migrant agricultural laborers from the Metema 
and Humera areas admitted to the then Gondar Public 
Health College Hospital (10).  In patients treated for 
visceral leishmaniasis, the reported case fatality rate can 
vary between 5% and 15% (25).  In this study, the case 
fatality rate of HIV co-infected patients was 39.3%, 
whereas it was 13.3% among HIV negative VL patients.  
Similar results were seen in the Sudan among non HIV 
infected VL patients (21, 22).  The mortality rate in 
VL/HIV co-infected patients was very similar to the 2001 
Ritmeijer report which observed a mortality rate of 33% 
among Ethiopian patients (30).   
 
The HIV/VL co-infection has been called a deadly 
'gridlock', as both infections tend to mutually reinforce 
their impact on the immune system (26).  The overall 
high case fatality rate was explained by the high HIV 
seroprevalence in our study.   
 
The HIV epidemic induced a major change in the 
epidemiology and treatment outcome of VL.  As of 2000, 
Leishmania and HIV co-infections had been reported 
from 33 countries (26).  Efficient case management based 
on early diagnosis and treatment is the key to limiting 
morbidity and preventing mortality (7).  However, in this 
study, patients sought treatment late in the course of their 
illness as they came from distant and inaccessible areas, 
resulting in terminal complications of VL.  This might 
have its own impact on the treatment outcome.  
Moreover, the optimal medications and intensive care 
facilities were not available in the hospital. 
 
Although follow-up at 3 and 6 months was arranged for 
all treated cases, only 4 relapsed cases, all of which were 
co-infected with HIV, showed up for follow up visits.  
The relapse rate has been reported to be as high as 50%  
in HIV co-infected individuals (7, 13).  The inability of 
the antibody response to control the parasite, and the 
absence of specific T-cell immunity to leishmania species 
can explain the high number of relapses (32). 
 
Using logistic regression, the independent variables 
predicting mortality were: age > 20 years, bleeding 
tendency, BMI of 15 and below, and HIV co-infection, in 
increasing order.  Patients aged > 20 years were more 
than twice as likely to die of VL as those 20 years and 
below.  Visceral leishmaniasis cases with bleeding (at 
least once) were 3 times as likely to die as those with no 
bleeding.  Individuals with body mass index of less than 
15 were more than 3 times as likely to die as those with 
BMI of 15 and above.  HIV co-infected visceral 
leishmaniasis patients were more than 4 times as likely to 
die as HIV negative patients.  Hemorrhage, low body 
mass index and HIV co-infection were also among the 
predicators of death in Ethiopian VL patients, as was 
previously reported (16). 
 
Conclusion and recommendation 
The number of visceral leishmaniasis patients admitted to 
Gondar University Hospital increased dramatically from 
year to year in the five year period this study covered.  
HIV co-infection and related case fatality rates were 
high.  HIV co-infection was prominent and was the most 
significant independent factor contributing to high 
mortality from VL.  We recommend a prospective case 
control study and critical care in treatment of HIV/VL 
co-infection, as it is a unique clinical entity. 
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